**Pharmacokinetics**

Soubhik Bhattacharyya

Assistant Professor

School of Pharmacy

ARKA JAIN UNIVERSITY Jharkhand, India

**soubhikbhattacharyya8505@gmail.com**

Snigdha Rani Behera

Associate Professor

School of Pharmacy

ARKA JAIN UNIVERSITY Jharkhand, India

**sni\_roldy@yahoo.com**

GowriSankar Chintapalli

Assistant Professor

School of Pharmacy

ARKA JAIN UNIVERSITY Jharkhand, India

**chintapalli.sankar@gmail.com**

**Abstract**

Pharmacokinetics pertains to the scientific investigation of the dynamic processes involved in the interaction between a medicine and the human body. The primary focus of this study is the examination of the processes involved in the absorption, distribution, metabolism, and elimination of medications. However, it can also be utilized to evaluate the temporal patterns of both endogenous compounds and exogenous toxicological agents originating from the environment. A comprehensive understanding of the four fundamental pharmacokinetic parameters is crucial for the toxicologic pathologist to effectively comprehend the potential utility of pharmacokinetics. An overview of allometric scaling is offered throughout the discussion of the non-compartmental and compartmental techniques for finding in vivo pharmacokinetic (PK) parameters. The consideration of compound permeability involves the examination of brain penetration and intestinal absorption. This comprehensive analysis encompasses various aspects, including the volume of distribution, plasma protein and tissue binding, as well as systemic, hepatic, renal, and biliary clearance, for both small and large compounds. The process of determining the pharmacokinetic (PK) parameters of a metabolite after the administration of a new chemical entity (NCE) is elucidated in the metabolite kinetics section. In conclusion, this section provides an overview of PK/PD reviews and their integration with mathematical models that are employed to depict pharmacodynamics (PD). These models aim to establish the correlation between the concentration of a new chemical entity (NCE) or compound at the specific site of action and the resulting effect.

**Keywords**: pharmacokinetics, compartment model, i.v. Bolus, i.v. Infusion, extravascular model.

1. **Introduction.**

Pharmacokinetics (PK) refers to the investigation of the distribution and movement of xenobiotics (including drugs, chemicals, and new chemical entities) within an organism following administration. In contrast, pharmacodynamics (PD) involves the examination of the interplay between the concentration of a substance or new chemical entity at the site of action, the specific targets for therapeutic intervention (such as receptors, transporters, or enzymes), and the magnitude of the resulting therapeutic response. The fundamental differentiation between pharmacokinetics (PK) and pharmacodynamics (PD) can be succinctly summarized as follows: PK pertains to the processes through which the body interacts with the drug, whereas PD pertains to the effects of the drug on the body [1]. Both domains of investigation are essential in assessing the pharmacological effectiveness and distribution patterns of substances/New Chemical Entities (NCEs) within the human body [2]. These domains can be influenced by several experimental and clinical factors, including gender, species, age, and illness condition.

**Dose of drug administered**

 **Absorption**

 **Distribution**

**Drug in tissue of distribution**

**Drug concentration in systemic circulation**

 **Elimination**

**Drug metabolised or excreted**

**Drug concentration at site of action**

 **Pharmacological Effects**

 **Clinical Responses**

 **Toxicity Effectiveness**

 **Fig 1: Mechanism of action of the drug in the4 body**

* 1. **Absorption, Distribution, Metabolism and Excretion.**

The process of absorption and distribution is subject to the effect of several physicochemical parameters. The maximum level of drug concentration in the bloodstream is achieved at the point of maximal absorption into the systemic circulation from the site of delivery. Chemicals are commonly transported by dispersion within pores, thereafter undergoing metabolism and elimination processes, predominantly facilitated by the liver and kidneys [2]. Numerous transporter proteins are also involved in the transcellular processes of absorption, distribution, or excretion. The solute carriers (SLC) and ATP-binding cassette (ABC) transporters play a significant part in the processes of absorption, distribution, and excretion, as stated in the field of Drug Metabolism. The book chapter provides a comprehensive account of the various factors influencing pharmacokinetics, with a particular focus on variables related to metabolism. These variables encompass a range of influences, such as hereditary factors, disease conditions, age-related changes, lifestyle choices, and dietary patterns. The concentration-time profiles following intravenous injection of a chemical often exhibit a slow decline in blood concentrations, characterized by a half-life (t1/2), which is the duration required for the concentration to decrease by half. After the medicine is administered orally, there are distinct phases of absorption and periods during which excretion becomes dominant. Substances such as the antibiotic gentamicin, which are absorbed into bone, muscle, and kidney, may exhibit multi-compartmental models because to the quantity and timing of distribution equilibria and release from tissues. The initial phase, also known as the first phase, in a two-compartmental model is characterized by the combined effects of distribution to various body tissues and elimination, leading to a rapid decline in blood concentration. The subsequent stage, commonly referred to as phase 2, involves the uniform distribution of the body's various tissues and fluids, with a primary focus on their subsequent elimination from the body.

**1.2.1 Absorption**

Absorption typically occurs subsequent to oral administration by passive diffusion of the non-ionized state. The extent of passive absorption is significantly impacted by the pKa or pKb values, as well as the pH of the surrounding environment and the specific tissue being targeted. Given that the stomach has a pH of 2, it may be inferred that the ionized form would be favored. The use of an antacid to manage an ulcer in a patient would lead to an increase in the pH of their stomach. Consequently, this alteration in pH would result in a reduction in the number of ionized molecules and an increase in passive absorption. According to the literature, it is possible for other compounds to undergo active transport or facilitated diffusion while moving across a concentration range [3]. SLC transporters belonging to the organic cation transporter (OCT) and organic anion transporter (OAT) families serve as instances of facilitated transport routes. Exemplary substrates for the organic anion transporter (OAT) superfamily encompass digoxin, rifampicin, penicillin G, salicylate, as well as quinine and quinidine for the organic cation transporter (OCT) superfamily. The active efflux transporter proteins from the P-glycoprotein (P-gp) family have the capability to transport drugs back into the lumen. This process serves to restrict drug absorption and promote their elimination by urine and biliary clearance. The resistance exhibited by certain individuals towards vinca alkaloids like as vinblastine, vincristine, vindesine, and vinorelbine can be attributed to their status as P-glycoprotein (P-gp) substrates. The volume of distribution (VD) might change depending on how transporters are acting. For instance, blocking liver-based efflux and uptake transporters may lessen the risk of VD. It is believed that flavonoids, including iso-orientin, which are found in many plants and have anti-oxidation, anti-inflammatory, anti-cancer, and antidiabetic properties, undergo substantial first-pass metabolism. The low penetration and substantial degradation of polyphenols and tanshinones in danshen (Salvia miltiorrhiza), a Chinese remedy, have enabled the development of intravenous formulations for the treatment of cardiovascular diseases and angina. In order to comprehend the bioavailability of a substance, it is crucial to assess the relative proportion of the substance that reaches the systemic circulation following oral and intravenous administration. This can be achieved by comparing the elimination time between the two routes of administration or by administering the intravenous dose in the form of a stable isotope-labeled version. This has the added benefit of cutting down on the number of animals needed, cutting down on the amount of time it takes to conduct the studies, and doing away with the need for a washout interval in between doses when it is done in animal trials. An example of a substance that can be dosed via many channels is Artemisin, an antimalarial phytochemical isolated from Artemisia annua. It can be administered intravenously, intramuscularly, orally, or via rectal route. Artemisin has a 30% bioavailability when taken orally due to first-pass metabolism. Morphine is an additional natural substance that has a sizable first-pass effect and is consequently delivered intravenously. Because it breaks down in the stomach's acid, Penicillin G cannot be used orally. The utilization of mistletoe leptins and quaternary amines, such as tubocurarine derived from Chondrodendron tomentosum, in adjunctive cancer therapy necessitates their administration via injection due to their inability to be absorbed. Conopeptides, such as Ziconotide and Contulakin-G derived from Conus geographus, are characterized by their large size and charged nature, which pose challenges for their transmembrane transport. Moreover, these peptides are susceptible to degradation by peptidases following oral or intravenous administration [4]. For the effective functioning of these volatile compounds, it is imperative that they are administered intrathecally, specifically targeting the spinal fluid. The carrier substance has the potential to be modified in order to enhance the oral bioavailability. The utilization of a "phytosome" is a prevalent approach in the field of lipid-soluble medicines, wherein the active constituents of the plant are affixed to phospholipids possessing a single hydrophilic tip and a pair of hydrophobic tails. Various formulations containing Ginkgo biloba, milk thistle, grape seed, green tea, hawthorn, and ginseng have been employed for this purpose. The bioavailabilities of hyperforin and hypericin, which are the active constituents found in Hypericum perforatum (commonly known as St. John's Wort), were significantly enhanced by approximately threefold when lipophilic soft-capsules made of gelatin and containing the natural surfactant lecithin were employed, as opposed to using commercially available hard-shell capsules lacking a surfactant. In addition, Silipide, a lipophilic compound of silybinphospatidylcholine, was developed with the aim of enhancing the oral bioavailability of silybin derived from milk thistle. The maximal plasma concentrations of Ginkgolide A, B, and Bilobalide extracted from G. bilboa were observed to increase by approximately twofold when administered as a phospholipid complex rather than in their unbound state. Research has been undertaken to investigate the enhancement of solubility and absorption through the examination of oligoethylene glycol chains, membrane carriers, and lipophilic derivatives of natural substances. Furthermore, the development of pH-responsive nanoparticles has been achieved for the purpose of enhancing the bioavailability of pharmaceuticals, such as andrographolide extracted from Andrographis paniculata, while simultaneously restricting drug delivery exclusively to the tumor site. The prediction of compound absorption can be achieved through the utilization of in vitro research methodologies, such as the employment of Caco-2 permeability models. This model incorporates a cell line derived from a patient with colorectal epithelial cancer. The absorption process is influenced by various factors, including the octanol-water partition coefficient, molecular weight (MW), number of hydrogen-bond donors, and number of hydrogen-bond acceptors. These factors have distinct impacts on the absorption mechanism. A chemical is considered to be in violation of Lipinski's "rule of 5" if the logarithm of the partition coefficient (logP) exceeds 5, its molecular weight (MW) exceeds 500, the number of hydrogen bond acceptors exceeds 10, or the number of hydrogen bond donors exceeds 5. A chemical compound is expected to exhibit limited absorption or penetration capabilities if it possesses two or more violations. The compounds containing both a fatty acid chain and a benzene group, namely yuanhuafine and yuanhuapine, exhibited limited absorption compared to other constituents present in Daphne genkwa. This particular plant is utilized in Traditional Chinese Medicine due to its various therapeutic characteristics, including diuretic, antitussive, expectorant, abortifacient, and anticancer effects.

**1.2.1.1 Factors affecting Absorption**

**Influence of pH**

The absorption of a lipid-soluble medication is boosted upon consumption. The pH of the surrounding solution for weak electrolytes exerts an influence on both the degree of ionization and the rate of medicine absorption. The observed dissimilarities in medication absorption patterns between the two structures can be attributed to the significant disparity in hydrogen ion concentrations between the small intestine and stomach. Aspirin, an organic acid, possesses a pKa value of 3.49, representing the negative logarithm of its dissociation constant. This characteristic is relevant in the context being discussed, as it serves to illustrate the influence of pH [5]. Aspirin often exists in a nonionized state when exposed to gastric acid with a pH range of 1 to 3. This characteristic aids in its passage through the stomach mucosa and subsequent absorption into the bloodstream. Nevertheless, due to the plasma's pH of 7.4, the aspirin undergoes significant ionization, resulting in the anionic species having limited ability to return to the gastrointestinal tract due to its low lipid solubility. When equilibrium is attained, the concentration of nonionized aspirin molecules is equivalent on both sides of the membrane. However, the total quantity of the medication, encompassing both ionized and neutral forms, is notably greater on the plasma side. The computation of the relative drug concentration in each compartment can be achieved by utilizing the Henderson-Hasselbalch equation.

$$(Log base (A\^-))/(acid (HA)) = pH – pKa $$

The phenomenon of ion trapping is observed when drug molecules exhibit an uneven distribution across the gastrointestinal membrane due to the presence of a pH gradient. The perpetuation of this partitioning is facilitated by the energy-demanding release of hydrogen ions (H+) by the stomach's parietal cells, as part of a biological process. Theoretically, the majority of acidic drugs have the potential to be sufficiently absorbed through the gastrointestinal mucosa. This is because only a few number of organic acids possess a pKa value that allows for significant ionization at the pH level of the stomach. However, this statement does not hold applies to bases like as codeine, which has a pKa value of 7.9. The ionization of codeine is predominantly facilitated by the acidic environment of the stomach, resulting in little absorption of the drug beyond the gastric region. At the pH level of the stomach, only bases that are exceedingly weak undergo deprotonation and become nonionized, allowing them to be absorbed. Ion trapping occurs within the lumen of the stomach before the process of absorption takes place. Interestingly, forensic medicine occasionally utilizes this. Substances possessing an organic foundation that induce intoxication encompass heroin, cocaine, and amphetamine. Chemical substances frequently accumulate within the stomach by traversing the gastric membrane in a counterintuitive manner, even in cases where they are supplied intravenously. The examination of gastric contents often offers insights on inquiries pertaining to intravenous overdose. Upon entering the small intestine, the acidic stomach fluid is promptly neutralized by pancreatic, biliary, and intestinal secretions. The pH of the proximal part of the gut ranges from 3 to 6, but the more distal regions have a neutral pH. In more alkaline conditions, aspirin undergoes a transformation into its anionic form, while a significant proportion of codeine molecules experience a loss of their positive charge. Due to the slight pH variation observed throughout the intestinal mucosa, basic pharmaceutical compounds are often favored over acidic ones for absorption in the small intestine. However, it is worth noting that the phenomenon of ion trapping is not as extensively observed in this context. The differences in intestinal absorption dependent on pH are mostly focused on the pace of uptake rather than the magnitude of uptake. As expected, the discrepancy in electrolyte absorption between the stomach and the small intestine is temporarily resolved when gastric contents are neutralized through the use of antacids or consumption of food.

**Mucosal surface area**

A significant differentiation between drug absorption in the intestinal tract and the stomach lies in the intraluminal surfaces that are accountable for drug uptake. Apart from a limited number of mucosal irregularities known as rugae, the lining of the stomach bears resemblance to a seamless sac enveloped by a substantial layer of mucus. In contrast, the mucosa of the small intestine has a particular adaptation for the process of absorption. The Kerckring folds, villi, and microvilli collectively lead to a significant amplification of the effective surface area by a factor of 600. A small intestine of 4 cm in diameter and 280 cm in length would provide a surface area of 200 square meters available for the absorption of drugs. The absorption of drugs in the small intestine can be effective despite a high degree of ionization, owing to the favorable surface-to-volume ratio of this organ. Multiple studies have provided evidence indicating that compounds with pKa values below 8.0, classified as basic, as well as acidic drugs with pKa values exceeding 3.0, exhibit a strong propensity for translocation from the intestinal fluid to the plasma. Consequently, despite the favorable influence of pH variables on the absorption of aspirin in the stomach, a significant portion of approximately 90% of the drug is absorbed in vivo from the small intestine. Based on empirical evidence, it has been observed that the absorption rate of non-electrolytes such as ethanol is significantly higher in the intestines compared to the stomach.

**Gastric emptying**

The temporal aspect of gastric emptying plays a significant role in the process of medication absorption. This is due to the fact that nearly all compounds capable of traversing the gastrointestinal epithelium exhibit enhanced absorption in the small intestine. This is particularly true for organic bases, which are unable to be absorbed from the stomach. The constriction of the antrum of the stomach leads to gastric emptying. In individuals undergoing fasting, a recurring sequence of events occurs, characterized by alternating periods of inactivity lasting approximately one hour each, followed by progressively intensifying contractions over a span of 40 minutes. These contractions culminate in a brief episode of intense contractions that propagate from the stomach to the distal ileum. The ingestion of a pill or a small quantity of fluids has the potential to delay gastric emptying, resulting in the medication remaining in the stomach for a duration of around one hour. Extended antral and pyloric contractions subsequent to a meal facilitate the fragmentation of the consumed food and enable the discharge of fluids into the duodenum, while retaining food particles bigger than 1 mm in diameter within the gastric cavity. A typical meal comprising both liquid and solid components typically enters the duodenum approximately 30 minutes after consumption and undergoes a complete gastric emptying process lasting around 4 hours. In contrast, the ingestion of a glass of water on an empty stomach results in expedited transportation to the small intestine, whereby around 50% of the liquid is expelled from the stomach within a span of 15 minutes, and nearly the entirety of it is evacuated within an hour. The existence of adipose tissue is a crucial determinant in the deceleration of gastric emptying. In general, it is recommended that most oral medications be ingested on an empty stomach and accompanied by a sufficient amount of water. This approach optimizes the accessibility to the gastrointestinal mucosa while expediting the entry of drug into the small intestine. In certain instances, the consumption of a meal rich in lipids can facilitate the assimilation of a drug characterized by a substantial lipid composition but limited solubility in water. Instances of substances that exhibit enhanced absorption in the presence of lipids encompass the fat-soluble vitamins and the protease inhibitor saquinavir. In these instances, a more comprehensive assimilation compensates for the delayed gastric emptying induced by the chyme's elevated fat concentration. The duration of drug latency, which refers to the time interval between oral delivery and the onset of a drug's effects, is sometimes influenced by the rate of medicine absorption, which is commonly hindered by gastric emptying. Consequently, numerous drugs that are not related to each other exhibit latency durations of similar duration.

**Influence of dosage form**

The delayed onset of effect of orally administered drugs can be attributed to the time required for gastric emptying and mucosal barrier diffusion. However, it is important to note that there are certain situations where these processes do not significantly affect the rate of drug absorption. The predominant form of oral pharmaceuticals available in the market consists of capsules or solid tablets. In order for absorption to occur, it is necessary for these drugs to undergo dissolution inside the gastrointestinal fluid, as opposed to existing in a solution state. The rate of dissolution can play a crucial role in medication absorption, particularly when the molecule is designed to dissolve at a slow pace. In order to facilitate the dissolution process, it is necessary to disintegrate the tablet (or the capsule and its granules) to liberate the primary drug particles. When a medicine solution has a faster systemic effect compared to a solid formulation containing the same active ingredient, the dissolution process can be seen as the limiting factor in determining the rate of absorption. There exist instances wherein notable variations occur in the absorption of various dose formulations, resulting in discernible clinical disparities. The administration of aspirin can lead to a higher drug concentration in the bloodstream after 30 minutes when delivered in a solution compared to a solid tablet, with the former exhibiting a twofold increase. The dissolution process is likely a significant contributing component, although it remains questionable whether this variability may be solely attributed to medicine dissolution or potentially influenced by other factors, such as the accelerated gastric emptying commonly observed with liquid formulations. Pharmaceutical makers often leverage the influence of dosage form on the process of drug absorption. Enteric-coated tablets are commonly produced to inhibit the premature release of some drugs within the gastric environment. An enteric coat is composed of a film consisting of shellac or an other polymeric material. In an acidic environment, the coating exhibits insolubility; yet, it undergoes disintegration to facilitate the breakdown of the tablet inside the alkaline milieu of the small intestine. Although these preparations are often beneficial, the increased variability in patient response negatively affects their effectiveness. The duration required for the tablet to transit from the stomach to the duodenum is a critical determinant, as the commencement of drug absorption is contingent upon the tablet's arrival in the duodenum. The duration of a solitary indissoluble tablet's uncontrolled transit from the gastric region to the intestinal region can vary, ranging from a few minutes to exceeding 6 hours. An additional approach to enhance the influence of formulation on medication absorption is the utilization of sustained-release formulations. These solutions are frequently designed to administer a consistent amount of medication into the gastrointestinal system over a period of 12 to 24 hours. Certain formulations also provide a first loading dose that is quickly absorbed. The implementation of a porous matrix, wherein the medication is distributed throughout the internal cavities and also deposited on the outer surface, can effectively facilitate a sustained release mechanism. An alternate approach involves the fabrication of drug-loaded spheres with diverse coatings that exhibit different dissolution rates. The topic of bioavailability serves as a prime example of the susceptibility of gastrointestinal absorption to alterations in drug composition. Historically, chemically similar drugs have often exhibited biological non-equivalence due to differences in formulation. In a particular study on tetracycline hydrochloride, a comparison was conducted between an aqueous solution and nine different formulations of the drug, which were produced by multiple manufacturers. Although the blood concentrations of seven different brands varied between 70% and 100% of the reference solution, it was observed that only 20% to 30% of the reference solution exhibited relative bioavailability for two specific items. The clinical significance of differences in bioavailability is heightened when dealing with drugs that exhibit poor absorption, have narrow safety margins, and disintegrate by capacity-limited pathways.

* + 1. **Distribution**

The distribution of xenobiotics is subject to the influence of several physicochemical properties of the molecule, such as its molecular weight (MW), degree of ionization, and lipophilicity, in a manner akin to absorption. As an example, theophylline has a lower degree of tissue dispersion of the methylxanthine compound compared to caffeine, mostly due to its somewhat lower lipid solubility. Plasma protein binding is a factor that can reduce the extent of blood distribution to remote locations. Basic pharmaceuticals typically exhibit binding affinity towards certain sites on α-globulin and 1-acid glycoprotein, whereas acidic drugs predominantly bind to albumin. The Amanita, Galerina, and Lepiota genera of mushrooms contain a higher proportion of amatoxins that can distribute more extensively within the body due to their absence of protein binding properties. In contrast, the protein-bound portion of paclitaxel (taxol), a chemotherapeutic agent obtained from the bark of Taxus brevifolia, often known as the Pacific Yew, ranges from 0.89 to 0.98. Camphor, characterized by a moderate affinity for lipid molecules and its tendency to evaporate easily, demonstrates a moderate level of plasma binding, with around 61% of the compound being linked to plasma proteins. Similar to the case of polyphenols in Type II diabetes, the presence of excessive glucose can lead to competition between glucose and polyphenols for binding to plasma proteins, hence potentially impacting plasma binding and subsequent physiological processes. Furthermore, the protein-polyphenol interactions in plasma are attenuated due to protein glycation. Various substances can display different levels of dispersion inside red blood cells. The concentrations of tetrahydrocannabinol in plasma are approximately twice as high as those in whole blood, resulting in a greater quantity of the substance accessible for distribution. This is due to the limited transport of tetrahydrocannabinol into red blood cells. Compartmental models are commonly employed for the purpose of delineating distribution. The presence of two compartments can arise when there is a decrease in the concentration of a tissue or fluid, which is then accompanied by an increase in the number of other tissues that reach a state of equilibrium with each other. In the context of human physiology, it has been observed that andrographolide, which is a pharmaceutical compound obtained from the plant Andrographis paniculata, exhibits a two-compartmental model. When administered at the same dosage, a single drug has the potential to exhibit both one-compartmental and two-compartmental models across multiple people. Out of the total cohort of 15 participants, it was observed that four individuals exhibited one-compartmental models with administration of andrographolide, whereas the remaining 13 persons had two-compartmental models. The duration allocated for the sample process has an impact on the number of compartments that are selected. For example, the three-compartmental models of vincristine, vinblastine, and vindesine are only observable when plasma concentrations are monitored for a duration of 48 hours.The average volume of circulating blood is around 5 liters, with a plasma volume of approximately 3 liters. It is inside the plasma volume that the distribution of chemicals takes place. The average adult human body comprises around 42 liters of water in total, with 25 liters classified as intracellular fluids and the rest fluids, such as plasma, categorized as extracellular. The measure of dispersion throughout the organism is denoted by the observed apparent volume of distribution (VD) in liters per kilogram. drugs with low volume of distribution (VD) often have a high degree of plasma protein binding and an elevated propensity for competitive interactions in comparison to drugs with high blood concentration. Individuals with a large volume of distribution (VD) have low blood concentrations due to their significant tissue-binding capabilities. The apparent volume of distribution (VD) is modified when a chemical is administered orally by multiplying it with the bioavailability factor. The bioavailability of a substance is often indeterminate, leading to the use of the notation VD/F to denote the apparent volume of distribution. Most drugs typically exhibit a volume of distribution (VD) ranging from 0.1 to 10 L/kg, which corresponds to approximately 40% to 0.4% of the total body water compartment. Digoxin exhibits a low therapeutic concentration of 0.92 ng/mL, which can be attributed to its elevated volume of distribution (VD) of 5.17.4 L/kg. The absence of a singular hydroxyl moiety in digitoxin, a compound derived from the same botanical source and exhibiting close chemical resemblance, results in a volumetric distribution (VD) value of 41 L/kg. Galantamine, a pharmaceutical agent characterized by a substantial volume of distribution (VD) owing to its limited affinity for protein binding and notable bioavailability, is derived from the botanical families Galanthus and Narcissus. It is employed in the therapeutic management of neurodegenerative disorders such as Alzheimer's disease. A multitude of chemicals exhibit a tendency to distribute selectively to particular organs. Traditional Chinese medicine use puerarin, derived from the root of the kudzu plant Pueraria lobota, for the therapeutic management of individuals afflicted with cardiovascular, neurological, and hyperglycemic disorders. The distribution of this substance in the kidney and pancreas of rat models provides evidence for its potential involvement in the augmentation of the diabetes condition [6]. Nevertheless, it has been demonstrated that the lung exhibits the highest levels, hence prompting ongoing efforts to ascertain the benefits associated with this particular organ. Lipophilic substances possessing therapeutic potential against various cancers encompass camptothecin and 10-hydroxycamptothecin, indole alkaloids derived from Camptotheca acuminate. These compounds exhibit the ability to be carried into tumor cells, kidneys, bone marrow, and the enterohepatic system in mice. Artemisinin, an antimalarial agent, exhibits a preferential distribution pattern in rats, with the highest concentration observed in the stomach, followed by the brain, kidney, and liver. Although constituting merely 0.8% of the overall body weight, it was observed that 8.1% of the administered hydroxytyrosol, an antioxidant included in olive oil, was found in the kidney during a span of 5 minutes following delivery. Previous studies have shown that the animal toxin tetrodotoxin, derived from the Tetraodontidae species, specifically the Japanese puffer fish, exhibits efficient absorption following subcutaneous injection in animal models. Furthermore, it has been observed that within a span of 2 hours, this toxin tends to accumulate mostly in the liver and kidneys. Lipophilic substances derived from Camptotheca acuminate, including 10-hydroxycamptothecin and camptothecin, exhibit transportability into several physiological compartments such as cancer cells, kidneys, bone marrow, and the enterohepatic system in murine models. There exists a body of research indicating that the administration of natural products in the form of a phospholipid complex may augment the dispersion of tissues. For example, when administered in conjunction with a soy phospholipid component, puerarin, a Chinese medication, exhibits enhanced dispersion inside the heart, lung, and brain tissues. The localization of natural products to specific tissues has been achieved by the implementation of several supplementary methodologies. The development of natural product-antibody conjugates has played a crucial role in the advancement of tumor-targeted therapy. In this study, a monoclonal antibody specifically targeting the glycoprotein expressed by human melanoma cells was conjugated with the ribosome-inactivating protein gelonin in a murine model to investigate its impact.

**1.2.3 Metabolism**

In addition to more moderate pathways such as carboxylation, cyclization, isomerization, dimerization, and transamidation, phase I reactions encompass oxidation (e.g., hydroxylation, dealkylation, and deamination), reduction, hydrolysis, or hydration. Specific metabolites play a crucial role due to their physiological effects. An example of a pharmacologically active metabolite derived from the antineoplastic agent vinblastine is generated via the process of deacetylation. In the metabolism of narcotics such as heroin and cocaine, plasma esterases, alongside hepatic enzymes, play a significant role in the process of drug degradation. Bacterial metabolism, along with anaerobic metabolic processes such as hydrolysis and reduction, occurs within the mucosal lining of the gastrointestinal system. Bacterial metabolism facilitates the conversion of flavonoids into phenolic acids, while lactase phlorizin hydrolase catalyzes the hydrolysis of these compounds. Semisynthetic analogues have the potential to be altered in order to achieve varying half-lives for compounds that exhibit inefficient metabolism, hence resulting in prolonged or reduced activity. As an example, it may be observed that the semisynthetic derivative known as everolimus exhibits a half-life of 30 hours, whereas the cancer drug sirolimus has a half-life of 60 hours. Phase II reactions encompass a range of biotransformation processes, including as glycosidation, methylation, acetylation, amino acid and glutathione conjugation, as well as glucuronide, sulphate, and amino acid reactions. While it has been demonstrated that morphine-6-glucuronide has activity as a metabolite, the majority of glucuronide conjugates are considered to be inert. Glucuronide conjugates possess the ability to undergo enterohepatic circulation, a process facilitated by uridine 5'-diphospho-glucuronosyltransferases (UGTs), sulfotransferases, efflux transporters, and microbial enzyme-mediated deconjugation. This mechanism enables the recirculation of glucuronide conjugates inside the body, leading to extended drug activity and excretion. In animal studies, it was observed that the pharmacologically active constituents of the Traditional Chinese Medicine blend consisting of Coptidis rhizoma and Evodiae fructus, namely berberine, palmatine, and jatrorrhizine, exhibited three distinct peaks in a time concentration profile. This suggests a recurring process of these compounds being transformed into other substances.

* + 1. **Excretion**

The renal system is responsible for the filtration of a wide range of chemicals, which are subsequently eliminated from the body by the excretion of urine or feces. The three primary mechanisms of renal excretion include filtration, secretion, and tubular reabsorption. In individuals who are young and in good condition, the typical renal nephron has the capacity to filter approximately 100-130 mL of blood per minute. The pH-dependent nature of tube reabsorption is evident in weak bases and acids with pKa and pKb values within the physiological pH range. The pH of urine undergoes variations in response to dietary intake, exhibiting a range between 4.5 and 7.5. Consequently, in cases where the ionized water-soluble forms are predominant, salicylic acid is more prone to being excreted in alkaline urine, while morphine tends to be excreted in acidic urine. The administration of sodium bicarbonate injection can be employed as a means of regulating excretion through the process of alkali diuresis. As an example, the process of alkalinization results in a reduced percentage (about 2235%) of ephedrine being excreted, while leading to an increased proportion (around 1124%) of norephedrine excretion. Additionally, alkalinization causes approximately 7080% of ephedrine to be eliminated without undergoing modification, with a minor fraction (4%) being excreted as norephedrine. In contrast, the process of filtering is contingent upon the molecular weight (MW) of the chemicals involved, hence rendering protein-bound medications and compounds with MWs over 500 unsuitable for this method. Certain ions can undergo active tubular secretion from the blood into the kidney through a range of uptake and efflux transporters located in the proximal convoluted tubule of the kidney. Carrier-mediated mechanisms play a role in the secretion of penicillin [7]. The rationale for co-administering probenicid with penicillin to prolong its efficacy stems from the observation that some weak acids possess the ability to competitively interact with the carrier protein. For example, ephedrine is typically excreted in the urine within approximately Furthermore, OATs also release salicylates and glucuronide metabolites, whereas morphine is secreted by cation transporters. The high renal clearance of atropine is attributed to its tubular secretion. The process of conjugation and subsequent deconjugation of biliary excretion can result in enterohepatic circulation, which serves as a notable pathway for elimination. In order to directly observe biliary excretion, invasive approaches have been employed to investigate the effects of digoxin, antibiotics, and quercetin on healthy human volunteers. Transporters belonging to the ABC B (BSFP and MDR1) and ABC C (MRP1 and 2) families have a role in the process of biliary excretion. Escin, a mixture of triterpenic saponins with anti-inflammatory properties, is derived from the seeds of the horse chestnut tree (Aesculus hippocastanum). In animal studies, it has been observed that around 66% of the administered dose of escin is largely excreted into the bile. The excretion of morphine-3-glucuronide into the bile in rat models has been observed to account for around 20% of the total amount. This mechanism has been associated with the transporter MRP 3. Vinca alkaloids, namely vinblastine, vincristine, vindesine, and vinorelbine, are expelled through the biliary system and feces in rats, canines, and humans. The process of deactivation during metabolism necessitates the elimination of the endoperoxide structure, mostly facilitated by the enzyme CYP 2B6. While the presence of metabolites has been detected, the underlying process responsible for their formation remains undetermined. When a chemical demonstrates first-order kinetics, the rate of elimination can be quantified by employing the concept of half-life (t1/2). Certain drugs consist of many chemical compounds that has distinct half-lives. An example of a Chinese pharmaceutical formula, Shakuyakukanzoto, comprises Glycyrrhizae (liquorice) and Paeoniae (peony) and is employed for the treatment of muscle cramps. The constituents of this formula possess varying half-lives, with paeoniflorin exhibiting a half-life of 1.7 hours and glycycoumarin having a half-life of 15 hours. Consequently, a pharmaceutical compound is developed that exhibits both prompt and enduring efficacy in alleviating muscular spasms and sustaining analgesic effects. This achievement is attributed to the synergistic interplay among a minimum of six distinct pharmacokinetic constituents. Clearance, sometimes expressed in units of mL/min/kg, refers to the quantity of pharmaceuticals that is eliminated from the bloodstream or plasma per unit of time by various organs responsible for drug clearance. This term is employed to delineate the process through which the liver, kidneys, and other organs responsible for detoxification metabolize and eliminate various chemicals. The clearance of an organ is determined by its extraction ratio, denoted as E. The extraction ratio represents the proportion of a substance that is cleared from the plasma by the organ during its transit through the organ. E is an outcome that arises from the activity of metabolic enzymes or transporters, the binding of proteins, and the flow of blood within organs. The determination of total body clearance involves the summation of individual organ clearances. The concept of clearance is occasionally represented as the ratio of the elimination rate constant to the volume of distribution (CL/VD), which serves as an indicator of the molecule's persistence within the body. This is due to the fact that a higher volume of distribution leads to increased persistence of the molecule in the body. An elevated renal clearance would indicate robust processes of secretion, filtration, and comparatively limited reabsorption. In the case of compounds that undergo substantial hepatic metabolism, a heightened hepatic clearance would be expected.

* 1. **The Pharmacokinetic applications.**

**Design of dosage regimens:**

A dosage regimen can be developed through a diverse range of methodologies. The initial dose of the medication is typically determined by utilizing established population pharmacokinetic parameters found in existing literature. These parameters are then adjusted based on the patient's diagnosed condition, pathophysiology, demographic information, known allergies, and any other relevant factors that may impact how well the patient responds to the prescribed dosage. The dosing strategies are typically based on manually completed pharmacokinetic calculations.

The calculation accuracy is increased, the calculations are made "easier," and there is an added benefit of maintaining a good documentation schedule with computer automation and pharmacokinetic software packages.

* **Nomograms and Tabulations in designing dosage regimen,**

An initial set of pharmacokinetic variables for drug dosing in specific patients, for whom patient-specific parameters are unknown, are often estimated using nomograms or equations that characterize the relationships between pharmacokinetic parameters in a population and patient characteristics (e.g., age, weight, gender, disease states, interacting drugs, environmental factors-food & smoking).

Tabulation: The tabulated data may comprise loading and maintenance doses that have been adjusted to account for patient demographics, such as age and weight, as well as specific medical conditions, such as renal insufficiency.

The topics to be discussed include the transition from intravenous administration to oral administration of medication, the establishment of appropriate dosage and dosing intervals, and the considerations for drug dosing in certain populations such as the elderly, pediatric patients, and individuals who are obese.

The pharmacokinetics of drug interactions.

Drug-drug interaction refers to the phenomenon in which the administration of one medication (known as the precipitant drug) alters the effects of another medication (referred to as the object drug) when taken concurrently. Metabolism-based drug interactions and various other elements can exert a substantial influence on the use and safeguarding of several medications.

Unexpected declines in drug concentrations or increases in metabolite concentrations can occur when medication metabolism is stimulated. Inhibition of drug metabolism can lead to the occurrence of the opposite effect.

The liver assumes a central role in the process of metabolism, with drug metabolism being primarily facilitated by CYP450, a widely recognized family of oxidative hemo-proteins. The process of drug metabolism is initiated by the stimulation of the CYP 450 enzymes in the liver.

Inhibition refers to the occurrence wherein certain medications and substances result in a reduction in the enzymatic capacity for drug metabolism. This phenomenon is commonly referred to as enzyme inhibition. There are two types of inhibition that might occur in a process.

There are two types of inhibition: direct inhibition and indirect inhibition. Enzyme induction refers to the occurrence of heightened drug metabolizing capacity in enzymes due to the influence of various medicines and substances.

Several pharmaceutical substances have the potential to induce a gradual elevation in the activity of liver enzymes. Consequently, this phenomenon has the potential to enhance the metabolic rate of either the same medications or different pharmaceutical substances. Phenobarbital has the ability to stimulate its own metabolism. Phenytoin and warfarin are examples of medications that will be discussed in this academic context.

**Therapeutic Drug monitoring:**

The concept that the pharmacological response is intricately linked to the concentration of a medication at its intended site of action forms the basis for the practicality of utilizing data on drug concentrations in plasma. Research conducted on individuals has provided insights into the optimal plasma concentration range of many drugs, which has been determined to be both safe and effective in the treatment of specific illnesses. The observed effects of the medicine are within the specified therapeutic range. If the dosage falls below the recommended threshold, there is an increased likelihood that the therapeutic benefits will not be realized. Conversely, exceeding the recommended dosage may result in adverse consequences.

Therapeutic drug monitoring encompasses the utilization of assay techniques to quantitatively determine drug concentrations in plasma, followed by the interpretation and application of the resulting concentration data to establish treatment regimens that prioritize safety and efficacy. Therapeutic concentrations of a medicine can be achieved more efficiently and with enhanced safety compared to the conventional approach of empiric dose changes. The provision of the safest approach to get optimal pharmacological therapy, along by thorough evaluations of the medication's clinical efficacy, is vital.

**Individualization of drug dosage regimen (Variability – Genetic, Age and Weight, disease, Interacting drugs).**

* Not all pharmaceutical substances necessitate a strict customization of the dosing regimen for each individual. Numerous pharmaceutical substances possess a substantial degree of safety, characterized by a wide therapeutic range, hence rendering the meticulous customization of dosage unnecessary. The United States Food and Drug Administration (FDA) has granted approval for the classification of certain pharmaceuticals as over-the-counter (OTC), thereby allowing the general public to purchase them without the need for a prescription. Over the recent years, the Food and Drug Administration (FDA) has granted over-the-counter (OTC) status to several prescription pharmaceuticals, including but not limited to ibuprofen, loratidine, omeprazole, naproxen, nicotine patches, and various others. Over-the-counter (OTC) pharmaceuticals and specific prescription medications, when used in accordance with instructions, are generally considered to be safe and efficacious for the intended purposes without the need for medical supervision.
* The individualization of dosage regimens is of utmost importance for medications characterized by a small therapeutic window, including digoxin, aminoglycosides, antiarrhythmics, anticonvulsants, and certain antiasthmatics like theophylline.

**• The rationale for therapeutic drug monitoring (TDM) and the recommended approach for implementing TDM protocols.**

* **The topic of interest is the correlation between pharmacokinetics and pharmacodynamics in the context of pharmacological therapy.**
* **This study aims to explore the therapeutic drug monitoring (TDM) of medications utilized in the treatment of various illness situations, including cardiovascular disease, seizure disorders, psychiatric problems, and organ transplantations.**

**The topic of interest is to the adjustment of dosage in individuals with renal and hepatic disease.**

* **Renal impairment refers to a condition characterized by a decline in kidney function.**
* **Pharmacokinetic considerations are important factors to take into account in the field of pharmacology.**
* **The overarching strategy for dosage modification in patients with renal disease.**
* **The assessment of Glomerular Filtration Rate (GFR) and creatinine clearance.**
* **Dosage adjustment considerations in patients with uremia.**

Nomograms are graphical tools that can be utilized to estimate dosing regimens for individuals with uremia. The nomograms are often constructed using serum creatinine levels, patient characteristics such as height, weight, age, and gender, as well as the pharmacokinetic properties of the medication. According to the scholarly work of Chennavasin and Brater (1981), it has been noted that every nomogram contains inherent inaccuracies in its underlying assumptions and pharmacological database.

Many approaches to dose modification in renal disease operate under the assumption that renal impairment does not impact the nonrenal clearance of the medication, and that the renal excretion rate constant in patients with uremia may be expressed as the product of a constant and the Cler.

ku = knr + a Cler

where knr is the non-renal elimination rate constant and a is a constant.

The equation bears resemblance to the subsequent equation, whereby 1/VD, and it can be employed for the development of a nomogram.

* **Extracorporeal removal of drugs.**
* **Effect of Hepatic disease on pharmacokinetics.**

**Population Pharmacokinetics.**

The field of population pharmacokinetics examines the variability in drug concentration among individuals within a population, with a focus on understanding the factors

Population pharmacokinetics (Pop-PK) refers to the scientific investigation of the variability observed in plasma drug concentrations among patient populations who are administered therapeutic doses of a particular medicine. This field of study aims to understand and characterize the differences in drug concentrations both between different patient populations and within the same population.

* **A Brief Overview of Bayesian Theory.**

The Bayesian theory was initially formulated with the objective of enhancing the accuracy of forecasts by the integration of subjective predictions with the incorporation of newly acquired facts. In the process of disease diagnosis, the physician has the ability to establish an initial diagnosis by relying on symptoms and conducting a physical examination.

Subsequently, the outcomes of the laboratory tests are obtained. Subsequently, the clinician formulates a novel diagnostic prognosis by integrating the aforementioned pieces of information. The Bayesian theory offers a framework for integrating previous knowledge, such as physical diagnosis, with new information, such as laboratory test findings, in order to get an updated probability for disease prediction.

* **The adaptive method or dosing with feedback**

The adaptive method or dosing with feedback is a technique that involves adjusting a certain parameter or variable based on the feedback received.

When administering medications with narrow therapeutic ranges, the starting dosage is determined by calculating it using average population pharmacokinetic parameters.

Following administration, plasma drug concentrations are collected from the patient. The reliability of the derived personalized patient pharmacokinetic parameters improves as additional blood samples are obtained from the patient. The aforementioned strategy is commonly known as the adaptive or Bayesian adaptive method with feedback, which employs a specialized extended least-squares algorithm.

* **Analysis of Population pharmacokinetic Data**
	1. **Rates and orders of reactions.**

After being administered, a medication undergoes a series of processes known as ADME, which govern the rates at which the drug is distributed, metabolized, and eliminated in the body. These processes ultimately determine the concentration of the drug at the specific location where it exerts its therapeutic effects, sometimes referred to as the "site of action." The aforementioned pathways exert influence on the duration, magnitude, and site of onset of the pharmacological response [4]. Hence, a comprehensive comprehension of these rate mechanisms is important in order to grasp the observed pharmacological effects of the administered medication. The symbol Y will be employed to denote a time-varying function (t). Consequently, the variable t represents an independent factor, while the variable Y denotes a dependent factor. In this chapter, the dependent variable (Y) can be represented by three potential factors: the mass of the drug in the body (X), the mass of the drug in the urine (Xu), or the concentration of the drug in the plasma or serum (Cp or Cs, respectively). A marginal alteration in the numerical value of Y will occur within a concise temporal interval, as seen below:

$\frac{dy}{dt}$ = $\frac{Y2-Y1}{t2-t1}$

The expression "dY/dt" represents the derivative of function Y with regard to an infinitesimal time period (dt), which denotes the instantaneous rate of change of Y.

The order of a process refers to the mathematical relationship between the size of the input and the time or space required to complete the operation. In the realm of scientific inquiry, one commonly encounters a range of customary directives and several categories of procedures.

In the realm of scientific inquiry, one commonly encounters a range of customary directives and several categories of procedures.

* zero order
* first order
* second order
* third order
* reversible
* parallel
* consecutive

Zero- and first-order processes are most useful for pharmacokinetics.

**

Fig 2: Process of change (zero order).

The zero-order process illustrates the dynamics of change inside a system operating under zero-order kinetics. The subsequent exposition presents the derivation of the equation governing a zero-order elimination process:

$\frac{-dy}{dt}$ = $K\_{O}Y^{0}$ (1)

In this context, K0 represents the zero-order rate constant, while the negative sign indicates a decrease over time, specifically in relation to elimination. Given that Y0 = 1,

$\frac{-dy}{dt}$ = K0  (2)

The equation presented provides unambiguous evidence that the variable Y undergoes a consistent alteration throughout time, as denoted by the presence of the constant K0, which represents the zero-order rate constant. This implies that the variation in Y is contingent upon factors beyond the quantity of Y existing at a specific moment. Several factors can influence the amplitude of this rate, such as the concentration of enzymes, the extent of light or oxygen absorption, and other relevant variables.

The integration of Eq. 1 yields the following:

$Y= Yo-Kot$ (3)

In the provided equation, the variable Y is used to denote the quantity present at a specific time t, whereas Y0 represents the initial quantity present at time zero. An example of the application of Y0 is its representation of the mass of a medication in the body at time zero, which is denoted as (X)t=0. In the context of an intravenous injection, the initial time point (t=0) corresponds to the administered dose (X0).



Fig 3: The rectilinear graph (R.L.) represents the behavior of a zero-order process. The variable X represents the concentration of the drug, while K denotes the rate constant..

Equation 3 exhibits similarities to other linear equations, specifically those of the form y = b - mx, where b represents the vertical axis intercept and k denotes the negative slope of the line. (Fig. 3).

Applications of zero-order processes

Zero-order processes have various applications in the field of pharmacology. These applications encompass the intravenous infusion of medications, the formulation and administration of drugs using controlled release dosage forms, and the delivery of drugs through transdermal drug delivery systems. To extend the application of the general zero-order equations to the scenario of zero-order drug elimination, suitable substitutes for the general variable Y will be employed. An illustration of the zero-order elimination rate equation may be observed by substituting X, which represents the mass of the drug in the body at time t, for Y in Equation 2.

$\frac{-dx}{dt}$ = K0 (4)

Whereas, the counterpart of the integrated Eq. 3 is X = Xt0 – K0t, or

$X = X0 - K0t$ (5)

The initial amount of medication in the body, denoted as Xt=0, is equal to zero. (For the purpose of intravenous administration, X0 represents the dose that is delivered.)

Unit of the rate constant (K0) for zero-order elimination of drug

Since dX in Eq. 4 has units of mass and dt has units of time, K0 must have units of mass/time (e.g., mg h-1). This can also be seen by the integrated Eq. 5: $K0t = X0 - X.$ Therefore,

$$K0 =\frac{xo-x}{t-to} mgh^{-1} $$

**First-order process**

Figure 4 illustrates the progression of a first-order process.

**

Fig 4: Process of change (First order).

The subsequent section presents the derivation of the equation governing a first-order elimination process. The inclusion of a negative sign in the equation signifies the decreasing nature of the quantity Y with respect to time.

$\frac{-dy}{dt}$ = $KY^{1}$ (6)

In the given context, Y represents the mass of a material that is undergoing a change or transfer, while K denotes the first-order elimination rate constant. However, since by definition Y1 = Y,

 $\frac{-dy}{dt}$ =$KY$ (7)

According to Equation 7, the rate of change of Y is influenced by the multiplication of the rate constant (K) and the mass of the substance experiencing the change or transfer, resulting in a decrease. Upon doing the integration of Equation 7, we obtain:

$Y= Y0e^{-kt}$ (8)

$ln Y= ln Y0- Kt$ (9)

or $log Y=log Y0-Kt/2.303$ (10)



Fig 5: The study involves the administration of a one-compartment intravenous bolus injection. The data collected from this study will be presented using three plots, which will utilize rectilinear (R.L.) co-ordinates.

The rate constant, denoted as K, is a variable that represents several quantities such as the mass of a drug in the body (X) or the concentration of the drug in plasma, among others.

The aforementioned set of three equations representing a first-order process can be graphically represented on a rectilinear coordinate system, as depicted in Figure 5. The utilization of semi-logarithm paper, commonly referred to as S.L. plot, is being discussed. Equation 8 can be graphed on semilogarithmic coordinates, with the dependent variable Y plotted against the independent variable t. The resulting outcome will have a vertical axis intercept denoted as Y0 and a slope represented by K/2.303, as illustrated in Figure 1.18.

Applications

The process of first-order elimination holds significant importance in the field of pharmacokinetics due to its predominant role in the elimination of medicinal medicines.

The general first-order equations discussed before are now being applied to the specific scenario of first-order drug elimination. In order to do so, we will substitute the necessary variables for the generic variable Y. An instance of substituting X, which represents the mass of the drug in the body at time t, for Y in Equation 6 results in the formulation of the first-order elimination rate equation:

$ \frac{-dx}{dt} = Kx^{1}= kx$ (11)

Upon integration of Eq. 11, we obtain:

$X = x\_{o}e^{-kt}$ (12)

where X0 is the dose of intravenously injected drug (i.v. bolus), or

$ln X= ln X0- Kt$ (13)

or $log X=log X0-Kt/2.303$ (14)

Unit for a first-order rate constant, K Eq. 11

$\frac{-dx}{dt}$ = K0

or d*X*/dt x *X-*1 = K, where units are mg h-1 x mg-1. So, K has units of h-1.

1. **Pharmacokinetic Models.**

The mathematical representation of the variation in the concentration of drug in the body over time following the administration of a dose sometimes involves the utilization of several equations, many of which incorporate exponential factors such as e x or e x. This observation implies that the processes of absorption, distribution, metabolism, and excretion (ADME) exhibit characteristics consistent with first-order kinetics when drugs are administered at therapeutic levels. Consequently, the movement of drugs inside the body may be facilitated by passive diffusion. Hence, a positive correlation exists between the measured plasma concentration and/or the quantity of medication excreted in the urine, and the dosage of the administered drug [4]. The phrase "linear pharmacokinetics" is derived from the direct relationship observed between the plasma concentration, the amount of medication removed, and the dose delivered. Due to the intricate nature of ADME processes, it is occasionally necessary to rely on a simplified model in order to provide a satisfactory explanation of the observed phenomena. In the field of pharmacokinetics, the compartment model has proven to be the most valuable model for this purpose. The human body is understood to consist of interconnected compartments that can be described mathematically.

* 1. **Compartmental Models.**

The utilization of the compartment concept in pharmacokinetics is necessary for accurately and adequately describing the data of plasma concentration versus time. This enables us to obtain precise estimates of fundamental pharmacokinetic parameters, including the apparent volume of drug distribution, elimination half-life, and elimination rate constant of a drug. Understanding these factors and choosing the proper equation form the foundation for determining the dosage regimen (including dose and dosing interval) necessary to achieve the required plasma concentration as well as the duration of action for a given drug. The choice of a compartment model is determined exclusively by the distribution properties of a medicine subsequent to its delivery. The mathematical expression necessary to describe the relationship between plasma concentration and time data is contingent upon the specific compartment model and route of drug delivery that is used. The chosen model should possess the capability to enable precise predictions in clinical scenarios [3]. As previously stated, the distribution characteristics of a medicine are of utmost importance in the process of selecting a model. In general, when the distribution of a medication throughout the body is slower, regardless of how it is administered, a greater number of compartments are needed to accurately describe the relationship between plasma concentration and time. Consequently, the equation used to model this relationship becomes more intricate. Based on this observation, it can be concluded that if the drug is rapidly distributed after being administered, regardless of the route of administration, a one-compartment model is sufficient for accurately and adequately describing the relationship between plasma concentration and time data. The words "rapid" and "slow" distribution pertain to the duration needed for the medicine to achieve distribution equilibrium within the human body. The achievement of distribution equilibrium signifies that the rate of medication transfer from the bloodstream to different organs and tissues, as well as the rate of drug transfer from various organs and tissues back into the bloodstream, have reached a state of equilibrium. Hence, the concept of rapid distribution implies that the speed at which a drug is transferred from the bloodstream to various organs and tissues, as well as its return to the bloodstream, reaches equilibrium immediately after the administration of the drug, regardless of whether it is administered within or outside the blood vessels. Hence, it can be observed that all organs and tissues exhibit comparable responses to the delivered medicine. The phenomenon of delayed distribution indicates that the state of distribution equilibrium is achieved gradually and within a specific timeframe, which can range from few minutes to a few hours, contingent upon the characteristics of the medicine being supplied [11]. Moreover, this observation implies that the medicine elicits distinct responses from the vasculature, tissues, and organs, indicating that the body can be conceptualized as consisting of two or perhaps more compartments. Highly vascularized physiological systems, such as the liver, kidney, and blood, can be consolidated within a single compartment known as the central compartment (compartment 1). Conversely, systems with lower perfusion rates, including bones, cartilage, fatty tissue, and others, can be grouped together and allocated to a separate compartment referred to as the tissue or peripheral compartment (compartment 2). In this particular model, the rates of drug transfer from compartment 1 to compartment 2 and vice versa will reach equilibrium at a time interval higher than zero, ranging from few minutes to a few hours. It is crucial to acknowledge that the choice of the compartment model relies on the presence of plasma concentration versus time data.

**Region of low concentration**

**Region of low concentration**

**Concentrated Solution**

 **Transfer**

Hence, the process of selecting a model is greatly influenced by the subsequent elements.

1.The interval at which blood specimens are extracted. It is strongly advised that plasma samples be obtained expeditiously, especially within the initial few hours subsequent to drug administration.

The sensitivity of the methodology utilized for the analysis of drug levels in plasma samples. The chance of selecting the appropriate 2. compartment model can be enhanced by employing a more sensitive analytical method, as assays with limited sensitivity may fail to detect subtle variations in the plasma concentration-time curve within the low concentration ranges.

3. The physical characteristics, such as the lipophilicity, of a pharmaceutical compound. As previously stated, the selection of the compartment model is influenced solely by the distribution features of a drug. The selection of an appropriate equation to appropriately define the plasma concentration versus time data is influenced by both the chosen model and the method of drug administration. The subsequent visual representations and instances aim to elucidate several of the concepts that have been addressed in this section.

**2.1.1 Intravenous bolus administration**

The one-compartment model is a theoretical framework commonly used in pharmacokinetics to describe the distribution and elimination of a drug within the The provided graph, denoted as Figure 1.8, illustrates a semilogarithmic representation of the relationship between plasma concentration and time data for a drug that has been supplied through an intravenous bolus dose. The nomenclature of a semilogarithmic plot is derived from the utilization of logarithmic coordinates on one axis (namely the y-axis) and linear coordinates on the other axis (the x-axis). The observed curve has a linear trajectory, so indicating the exclusive existence of a singular pharmacokinetic phase, specifically the elimination phase. Due to the intravenous route of administration, the medication does not undergo an absorption phase. The linear trajectory additionally implies prompt dispersion, indicating that the medicine is swiftly disseminated throughout the body. The data can be effectively and comprehensively explained by utilizing the mono-exponential equation provided below.

$Cp = (Cp)o e Kt$ (15)



**Fig 6:** The graph presented depicts the relationship between plasma concentration (Cp) and time subsequent to the intravenous injection of a medication that exhibits rapid distribution throughout the body. The plot is semilogarithmic in nature.

The variable Cp represents the plasma drug concentration at any given time t, while (Cp)o represents the plasma drug concentration at the initial time t=0.

It should be noted that the concentration against time plot has a singular phase, and the equation necessary to represent the data involves a single exponential term. This suggests that employing a one-compartment model is suitable in the present scenario.

**2.1.2 Intravenous bolus administration**

The two-compartment model is a theoretical framework commonly used in academic research to describe and analyze complex systems. It is a mathematical representation The data presented in Figure 7 provides unambiguous evidence of the presence of two distinct phases in the relationship between concentration and time. The initial phase, characterized by a curved pattern, corresponds to the process of drug distribution within the body. It is only after a certain period of time, denoted by a discontinuous perpendicular line, that a linear relationship becomes apparent. The point at which the concentration versus time graph starts to exhibit a linear relationship signifies the establishment of distribution equilibrium. This observation implies that the distribution of the medication is occurring at a gradual pace, necessitating the utilization of a two-compartment model in order to accurately describe its behavior. The plasma concentration versus time data will be characterized by a biexponential equation, which consists of two exponential terms.

Cp = Ae -αt + Be -βt  (16)

 **Distribution or α phase**

 **Cp (µg mL–1)**

 **Post-distribution or β phase**

 **Time (h)**

**Fig 7:** A conventional semilogarithmic graph illustrating the relationship between plasma concentration (Cp) and time subsequent to the administration of an intravenous bolus dose of a drug that exhibits gradual distribution within the body. In this context, A and a represent parameters linked to the distribution of the drug, while B and b represent parameters associated with the post-distribution phase of the drug.

It is important to acknowledge that Figure 7 presents concentration versus time data, which may be divided into two distinct phases. To accurately characterize this data, an equation incorporating two exponential factors is necessary. This observation suggests that a two-compartment model is suitable in this particular scenario.

**2.1.3 Extravascular administration: one-compartment model**

Extravascular administration can be accomplished through various routes: The many routes of drug administration include oral administration (in the form of tablets, capsules, suspensions, etc.), intramuscular administration (in the form of solutions and suspensions), subcutaneous administration (in the form of solutions and suspensions), and sublingual or buccal administration (in the form of tablets). The three routes of medication administration discussed are rectal administration (namely suppository and enema), transdermal drug delivery devices (specifically patches), and inhalation (specifically metered dose inhalers).



**Fig 8:** A conventional semilogarithmic graph illustrating the relationship between plasma concentration (Cp) and time (t) subsequent to the extravascular delivery of a dosage of a drug that exhibits fast distribution inside the body.

The figure depicted in Figure 8 illustrates the relationship between plasma concentration and time, which corresponds to a one-compartment model for a drug that is supplied through extravascular means. The profile consists of two distinct phases, namely absorption and elimination. The time it takes for a drug to begin exerting its effects is influenced by various factors, including the composition and presentation of the medication, the method by which it is administered, the physical and chemical characteristics of the drug, and other physiological aspects. The total systemic distribution of a pharmaceutical compound may not always be achieved due to partial absorption. Nevertheless, the profile unambiguously demonstrates the existence of a solitary phase during the post-absorption period. The selection of a compartment model is determined solely by the distribution property, and in this case, the profile consists of a single phase during the post-absorption period. Therefore, a one-compartment model is sufficient to precisely and adequately represent these data. However, in order to accurately represent the relationship between concentration and time data, it would be necessary to employ a biexponential equation. The subsequent equation might be utilized to characterize the data:

$Cp = Ka (Xa)t=0 /V (Ka – K) [e^{-kt} - e^{-kat}]$ (18)

$= KaFX0 /V (Ka - K) [e^{-kt} - e^{-kat}]$ (19)

The variables used in this context are as follows: Ka represents the first-order absorption rate constant, K represents the first-order elimination rate constant, (Xa)t=0 denotes the initial amount of absorbable drug at the absorption site, F represents the percentage of the drug that is absorbable, and X0 represents the dose that is supplied. It should be noted that the utilization of a one-compartment model would yield a precise depiction, given the presence of a solitary post-absorption phase. However, due to the existence of two distinct phases in the plasma concentration versus time data, the use of a biexponential equation becomes necessary for an exact portrayal of the data.

**2.1.4 Extravascular route of drug administration, two-compartment model**

****

**Fig 9:** A conventional semilogarithmic graph depicting the relationship between plasma concentration (Cp) and time subsequent to the extravascular delivery of a dosage of a drug that exhibits gradual distribution inside the body.

The data presented in Figure 9 provides unambiguous evidence of the existence of three distinct phases in the plasma concentration versus time profile for a medication delivered through an extravascular route. The three distinct stages encompass absorption, distribution, and post-distribution. It should be noted that within the depicted figure, a definite and easily identifiable differentiation can be observed between the distribution and post-distribution phases [9]. Moreover, the plasma concentration-time profile during the post-absorption phase has a striking resemblance to that observed in an intravenous bolus two-compartment model, as depicted in Figure 7. Hence, the aforementioned data can be adequately characterized by utilizing a two-compartment model, wherein the equation will encompass three exponential components corresponding to distinct phases, namely absorption, distribution, and post-distribution. It is important to emphasize that these compartments do not align with physiologically delineated regions (e.g., the liver does not constitute a compartment). In the event that the selected model fails to sufficiently depict the observed data pertaining to plasma concentration, an alternative model is put forth. The optimal selection of a model should prioritize simplicity while ensuring it is capable of adequately describing the observed facts. It is imperative to possess a comprehensive understanding of the kinetic aspects of a model when employing it for clinical prognostications.

* 1. **Non-Compartmental Models.**

This approach is alternatively referred to as the model-independent method.

* Non-compartmental models are utilized to characterize the pharmacokinetics of drug disposition by incorporating time and concentration parameters.
* These models can be employed for any compartment model, as long as the drugs or metabolites exhibit linear kinetics.
* This methodology, rooted in statistical moments theory, entails the acquisition of experimental data subsequent to the administration of a single dose of the drug.
* If one examines the temporal pattern of drug concentration in plasma as a statistical distribution curve, then

$MRT = AUMC/AUC$ (20)

* The mean residence time (MRT) refers to the average duration during which medication molecules remain within the body. MRT is alternatively referred to as the mean transit time and mean sojourn time. The variable MRT represents the cumulative duration of drug residence within the body, encompassing all drug molecules, as well as the overall count of drug molecules.  The equation MRTiv = 1 KE represents the relationship between the marginal rate of technical substitution (MRTs) and the elasticity of capital (KE) in an academic context.
* The mean absorption time (MAT) can be defined as the discrepancy between the mean residence time (MRT) and the mean residence time in the intravenous compartment (MRTIV) following the administration of a drug through an extravascular route.

$MAT = MRTⅇv – MRTiv$ (21)

* Clearance refers to the rate at which drug molecules are removed from the plasma, expressed as the volume of plasma cleared per unit time. It is possible to compute clearance without taking into account the compartment model.
	1. **Physiological Models.**

Physiological pharmacokinetic models are mathematical representations that elucidate the dynamics of drug distribution and elimination inside the human body, taking into account factors such as organ blood flow and the extent to which the drug permeates various organ compartments. Models are developed based on the established understanding of the anatomy and physiology of both humans and other animals. This study integrates physiological, anatomical, and physiochemical data.

MERITS

* The duration of the history of medication concentration in every organ or tissue should ideally be precisely described.
* This capability enables the provision of enhanced understanding of the process of drug distribution within the human body.
* The parameters of these models are representative of real physiological and anatomical measurements.
* This study aims to explore the potential of animal scale-up as a means to provide a logical framework for correlating pharmacological data across various animal species.

DEMERITS

* There is a need for increased demands for the availability of in vitro or in vivo data.
* The statistical assessment of uncertainty and variability poses greater difficulties.
* The successful creation and execution of a model necessitates the presence of suitable skills.

ASSUMPTION

* Drug exchange between interstitial water and capillary blood is thought to occur very quickly.
* The cell membrane exhibits a high degree of permeability to the medication.
* The capillary membrane does not present any hindrance to the penetration of drugs.
* It takes little time to establish a constant drug concentration ratio between organ and venous blood.

TYPES OF MODELS

* Blood flow limited model
* Physiologic Pharmacokinetic Model with Binding
* Membrane limited model

BLOOD FLOW LIMITED MODEL

The transport and distribution of drugs within the human body are influenced by factors such as organ blood flow and the extent to which the medication penetrates various organ areas.

At its most basic level, a physiological pharmacokinetic model assumes that the drug is limited by blood flow. The transportation of drugs to organs occurs by arterial blood flow, while their exit from organs is facilitated by the venous blood circulation [10].

The differential mass balance equations are formulated for each compartment in order to characterize the influx, efflux, accumulation, and depletion of the drug. These equations are solved concurrently with the use of computational tools.

Tissue compartment

Blood

 Cart, Qt Cven

The absorption of the medication into the tissues occurs swiftly, leading to the prompt establishment of a consistent ratio of drug concentrations between the organ and the venous blood. The aforementioned ratio represents the partition coefficient between tissue and blood.

$PTissue $= $^{Ctissue}/\_{Cblood}$ (22)

The symbol P represents the partition coefficient in this context.

The partition coefficient's size exhibits variability contingent upon the specific drug and the nature of the tissue involved. As an illustration, Adipose tissue exhibits a notable affinity for lipophilic medicines.

The measurement of blood flow to the tissue is denoted as Q, measured in milliliters per minute (mL/min), while the measurement of the rate of change in drug concentration over time within a specific tissue organ is denoted as

$d (Vtissue - Ctissue)/dt = Qt (Cin - Cout)$ (23)

$d (Vtissue - Ctissue)/dt = Qt (Cart - Cven)$ (24)

In this context, C represents the concentration of the medication in arterial blood, while C represents the concentration of the drug in venous blood. The concept of blood flow pertains to the measurement of the volume of blood that passes through a specific tissue or organ within a given timeframe.

**PHYSIOLOGIC PHARMACOKINETIC MODEL WITH BINDING**

The physiological pharmacokinetic model postulates drug distribution that is confined by flow, without any drug binding occurring to either plasma or tissues.

In actuality, numerous medicines exhibit varying degrees of binding to either plasma or tissue components.

In the majority of physiological models, drug binding is typically considered to follow a linear relationship, without saturation or dependence on drug concentration. The equilibrium state is reached between the bound and free forms of the medication in both tissue and plasma. Moreover, the unbound drug in the plasma and tissue achieves equilibrium at a rapid rate.

1. **Non-linear Pharmacokinetics.**

This phenomenon is commonly referred to as capacity-limited, dose-dependent, or saturation pharmacokinetics. When administered at lower doses, the medication exhibits first-order kinetics. However, at higher doses, it transitions to zero-order kinetics as a result of saturation, leading to its classification as Mixed Order Kinetics. Nonlinear pharmacokinetics are characterized by a deviation from first-order kinetics when the dosage is escalated. This deviation might be attributed to the saturation of an enzyme- or carrier-mediated system. Nonlinear pharmacokinetics exhibit some distinctive features. Firstly, the area under the concentration-time curve (AUC) does not exhibit a proportionate relationship with the administered dose. Secondly, the quantity of medication eliminated through urine does not demonstrate a proportional relationship with the dose. At higher doses, it is possible for the elimination half-life to exhibit an increase. The alteration in the dosage level leads to a modification in the proportion of metabolites generated.

Methods for detecting non-linearity in data

The objective is to ascertain the Css (steady state plasma concentration) at various doses and determine if Css exhibits a direct proportionality to the doses, indicating linear pharmacokinetics, or if it demonstrates nonlinearity, indicating nonlinear pharmacokinetics. This study aims to ascertain several crucial pharmacokinetic characteristics, including the fraction bioavailable (F), half-life (t1/2), and total clearance, across various dosages.

Any alteration in characteristics that are often considered constant results in non-linear pharmacokinetics. Causes of non-linearity

1. Drug Absorption
* When the absorption is limited by factors like as solubility or dissolution rate, for example in the case of Griseofulvin.
* When absorption occurs through carrier-mediated transport, saturation at greater doses leads to nonlinearity. This can be observed in substances such as Riboflavin and Ascorbic Acid.
* Saturation of pre-systemic gut wall or hepatic metabolism, such as in the case of Propranolol, can occur.
* Various factors, such as illnesses and the timing of administration (Chronopharmacokinetics), can lead to alterations in gastric blood flow and stomach emptying.
1. Distribution
* The phenomenon of plasma protein binding saturation, as observed in the instance of Phenylbutazone, is characterized by the inability of additional drug molecules to bind to plasma proteins beyond a certain threshold.
* The phenomenon of tissue binding sites becoming fully occupied, as observed in the instance of Imipramine. a. In both scenarios, there is an elevation in the concentration of the drug in the plasma and an increase in the volume of distribution (Vd) in the first case, while a decrease in Vd occurs in the second situation. b. The clearance of a drug with a high extraction ratio (ER) is significantly enhanced as a result of the saturation of the binding site.
1. Drug Metabolism
* The metabolic capacity is constrained by the saturation of enzymes or cofactors. Some examples of substances that can be considered are phenytoin, theophylline, and alcohol. To optimize the performance of the system, it is recommended to enhance the Cascading Style Sheets (CSS) while reducing the Computational Load (CL).
* An example of enzyme induction can be noticed in the instance of carbamazepine, where a drop in plasma concentration is observed upon repetitive treatment over a period of time. To enhance the coefficient of lift (CL), it is recommended to augment the angle of attack or modify the airfoil shape. Conversely, to reduce the coefficient of skin friction drag (Css), measures such as employing
* The occurrence of hepatotoxicity, alterations in hepatic blood flow, and the inhibitory impact of metabolites on enzymes are noteworthy factors to consider.

Drug Excretion

* The phenomenon of active tubular secretion, as exemplified by the case of penicillin. The renal clearance is reduced.
* Active tubular reabsorption occurs in the case of water-soluble vitamins and glucose. The renal clearance is enhanced.
* Induced diuresis, alteration in urinary pH, renal toxicity.
* The Michaelis-Menten kinetics model is employed to characterize the nonlinearity observed in pharmacokinetics.
* The Michaelis-Menten equation is a mathematical model that characterizes the rate of change, or velocity, of plasma drug concentration.

$ⅆc/ ⅆt = - VmaxC /km + C$ (25)

The symbol Vmax represents the highest attainable velocity of a given reaction, whereas the variable C denotes the concentration of the substrate or plasma drug. The Michaelis constant, Km, is equivalent to the substrate concentration, C, at which the reaction rate reaches half of its maximum value, Vmax.

• When the substrate concentration, C, is significantly lower than Km (C << Km), the equation simplifies to a first-order rate equation due to the constancy of both Km and Vmax.

$ⅆc /ⅆt = - VmaxC/ km + c = k\_{1}C $ (26)

• When the value of C is significantly higher than Km, the equation simplifies to a rate equation of zero-order.

$ⅆc/ⅆt = -Vmax$ (27)

• This study presents the elimination rates of drugs under different concentration levels. Specifically, it examines the zero-order elimination rates observed at high drug concentrations, the fractional-order elimination rates observed at intermediate drug concentrations, and the first-order elimination rates observed at low drug concentrations.

**Conclusion**

Having a comprehensive understanding of pharmacokinetics and pharmacodynamics will enhance clinician ability to make informed decisions regarding the selection of drugs, suitable dosages, and optimal dosing schedules for diverse patients. The significance of this matter lies in its relevance to professional anaesthetists, as the administration of multiple medications is necessary to attain optimal anaesthetic effects. The art of titrating anaesthetic pharmaceuticals, which involves the precise administration of these drugs, is often considered to be a manifestation of years of knowledge in this field. However, it is important to note that this subject can also be approached from a scientific perspective.

**References**

1. Meyer BH, Welch EH, Milner A, Möhr D. Applied pharmocokinetics. In: Milner A, Welch E, editors. Applied pharmacology in anaesthesiology and critical care. 1st ed. Medpharm Publications (Pty) Ltd; 2012. p. 1-32.

2. Shargel, L., & Yu, A. B. (2015). Applied Biopharmaceutics and pharmacokinetics (7th ed.).

3. Benet, L. Z., & Zia-Amirhosseini, P. (1995). Basic principles of pharmacokinetics. Toxicologic Pathology, 23(2), 115-123. <https://doi.org/10.1177/019262339502300203>

4. Jambhekar, S. S., Breen, P. J., & Royal Pharmaceutical Society of Great Britain. (2012). Basic pharmacokinetics.

5. Dowd, F. J., Johnson, B., & Mariotti, A. (2016). Pharmacology and therapeutics for dentistry - E-book. Elsevier Health Sciences.

6. Daneman, R., & Prat, A. (2015). The blood–brain barrier. Cold Spring Harbor Perspectives in Biology, 7(1), a020412. <https://doi.org/10.1101/cshperspect.a020412>

7. DeGorter, M., Xia, C., Yang, J., & Kim, R. (2012). Drug transporters in drug efficacy and toxicity. Annual Review of Pharmacology and Toxicology, 52(1), 249-273. <https://doi.org/10.1146/annurev-pharmtox-010611-134529>

8. Duckworth, R. M. (2013). Pharmacokinetics in the oral cavity: Fluoride and other active ingredients. Monographs in Oral Science, 125-139. <https://doi.org/10.1159/000350590>

9. Fan, J., & De Lannoy, I. A. (2014). Pharmacokinetics. Biochemical Pharmacology, 87(1), 93-120. <https://doi.org/10.1016/j.bcp.2013.09.007>

10. Gallardo, E., Barroso, M., & Queiroz, J. (2009). Current technologies and considerations for drug bioanalysis in oral fluid. Bioanalysis, 1(3), 637-667. <https://doi.org/10.4155/bio.09.23>

11. Zakeri-Milani, P., & Valizadeh, H. (2014). Intestinal transporters: Enhanced absorption through P-glycoprotein-related drug interactions. Expert Opinion on Drug Metabolism & Toxicology, 10(6), 859-871. <https://doi.org/10.1517/17425255.2014.905543>.